Today's Rundown Featured Story | | | Wednesday, January 9, 2019 Nearly a year after Tmunity Therapeutics raised $100 million to develop better and safer T cell treatments, the company is getting ready to present data, unveil new targets and boost its headcount in 2019. |
|
|
Top Stories Wednesday, January 9, 2019 Since Pavan Cheruvu—formerly Roivant’s chief people officer—took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player. Wednesday, January 9, 2019 SAN FRANCISCO—We certainly like to offer a full breakfast here at FierceBiotech, especially at the J.P. Morgan Healthcare Conference, where attendees have probably had to get a second mortgage for a three-day hotel stay. Monday, January 7, 2019 Biopharmaceutical science has the capability to drive change in our society and write a new storyline for public health. However, science alone will not achieve this change. So what can? Wednesday, January 9, 2019 Basilea Pharmaceutica has shared interim data from a registrational trial of ArQule-partnered cancer drug derazantinib. The oral FGFR kinase inhibitor achieved an objective response rate of 21% in the first 29 evaluable intrahepatic cholangiocarcinoma patients enrolled in the study. Tuesday, January 8, 2019 UroGen Pharma’s UGN-101 has triggered durable complete responses in 57% of the low-grade upper tract urothelial carcinoma patients enrolled in its phase 3 trial. The readout from the ongoing pivotal trial comes as UroGen performs a rolling NDA under the leadership of new CEO Liz Barrett. Wednesday, January 9, 2019 Roche’s senior VP of global oncology product strategy, Cindy Perettie, is jumping over to become the next CEO of Foundation Medicine, which the Big Pharma acquired last year through a $2.4 billion buyout. Wednesday, January 9, 2019 When she put cancer back on the front burner, GlaxoSmithKline CEO Emma Walmsley gave the company a big task. After all, GSK had traded away most of its oncology assets to Novartis. But with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says. Resources Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
